The global Group's commitment to fighting the Coronavirus epidemic

The KHB Group's commitment to combat the Coronavirus epidemic is global and Technogenetics, part of the KHB Group since 2015, is committed to the forefront of developing and distributing IVD kits capable of diagnosing and monitoring the virus. Kehua Biological Group (KHB), has brought together its strategic partners to provide solutions for clinical institutions and to respond to the various world diagnostic needs, showing great commitment and social responsibility to "focus on life and pursue excellence".

What are we doing

31/12/2019 - The first infections are reported by the Chinese government to the World Health Organization

01/12/2020 - Tianlong, a company controlled by KHB and partner of Technogenetics, has completed the research and development of the 2019-nCoV detection kit; this kit is used for the quantitative detection of the 2019-nCoV nucleic acid ORF1ab / N gene

03/02/2020 - The board of directors of KHB has agreed in the holding company Suzhou Tianlong, a company of the KHB Group, to donate more than 10,000 coronavirus nucleic acid extraction and detection reagents to Wuhan Union Medical College and the Wuhan Center for Disease Control and Prevention, supporting the fight against the new coronavirus epidemic at the forefront.

05/02/2020 - KHB with Shanghai Seaview Yu Enterprise and other enterprises of the Shanghai Chamber of Commerce, has donated a new nucleon acid detection reagent, developed by Tianlong (KHB subsidiary) to help the city of Xiangyang , Hubei province, also providing specialized support through its collaborators and donating other medical devices to support the diagnosis, isolation, and early treatment of the epidemic.

07/02/2020 - To date, 31.211 confirmed cases and 26,359 suspected cases have been reported across China. In this war against time, KHB, together with its partner companies Tianlong Technology, Aoran Bio, Aixing Bio, Heisen Meikang and many other IVD companies, formed a task force to establish a robust alliance dedicated to meeting the diagnostic needs of clinical institutions with effectiveness, precision and efficiency. The goal is to improve control systems for detecting new cases of coronavirus infection and work together to fight the epidemic.

The Group's commitment

KHB promptly reorganized its functions and the activities of its subsidiaries to provide equipment useful for the biochemical detection of the virus and assess the immune response of the infected.

Tianlong, a subsidiary of the KHB Group, was one of the first companies to lay the foundations for fighting the epidemic. On January 12, 2020 Tianlong completed the research and development of the 2019-nCoV detection kit; this kit is used for the quantitative detection of the 2019-nCoV nucleic acid ORF1ab / N gene.

The kit is currently in use at 155 nursing homes and 146 hospitals across China and the first cases of infection confirmed in the provinces of Yunnan, Sichuan and Shaanxi were detected by the new reagent. Tianlong employees have renounced the Chinese Lunar New Year holidays to ensure maximum efficiency of the production plants which have a production capacity of 10,000 tests per day.

In addition, after finding that many first aid labs experienced a high risk of infection for healthcare professionals due to aerosol transmission of the virus, the company immediately launched a research and development program to produce a sample storage solution. infected that ensures inactivation of the virus during the transfer and handling of samples. Currently more than 10,000 solutions have already been produced which have been destined for the various laboratories in the most affected areas.


Technogenetics, Italian subsidiary of the KHB Group since 2015, specializes in the research & development of diagnostic tests and IVD medical devices, with specific know-how in the field of infectious diseases, autoimmunity and chromosomal disorders.
It will act as a bridge to convey the Group's knowledge in Europe and all over the world, contributing on a global scale to fighting the coronavirus epidemic.

© Technogenetics 2021. All rights reserved